⌘K
t
Shield Therapeutics PLC filed its Block Listing 6 Monthly Return on 02 January 2026, covering the period from 01 July 2025 to 31 December 2025. During this period, the Shield Therapeutics Retention and Performance Share Plan's block scheme increased by 15,000,000 securities, from which 6,137,791 securities were allotted. The other three share schemes (Retention Share Plan, 2016 Company Share Option Plan, 2016 Long Term Incentive Plan) reported no increase or allotment of securities.
| Date | 2 Jan 2026 |
| Time | 11:06:43 |
| Category | Capital structure |
| ID | 4870N |
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Block Listing 6 Monthly Return
|
Name of applicant: |
SHIELD THERAPEUTICS PLC
|
|||
|
Name of scheme: |
Shield Therapeutics Retention Share Plan |
|||
|
Period of return: |
From: |
01 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
39,794 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
39,794 |
|||
|
Name of applicant: |
SHIELD THERAPEUTICS PLC
|
|||
|
Name of scheme: |
Shield Therapeutics plc 2016 Company Share Option Plan |
|||
|
Period of return: |
From: |
01 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
341,020 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
341,020 |
|||
|
Name of applicant: |
SHIELD THERAPEUTICS PLC
|
|||
|
Name of scheme: |
The Shield Therapeutics plc 2016 Long Term Incentive Plan |
|||
|
Period of return: |
From: |
01 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
24,273 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
24,273 |
|||
|
Name of applicant: |
SHIELD THERAPEUTICS PLC |
|||
|
Name of scheme: |
Shield Therapeutics Retention and Performance Share Plan |
|||
|
Period of return: |
From: |
01 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
2,870,838 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
15,000,000 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
6,137,791
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
11,733,071 |
|||
|
Name of contact: |
Lucy Huntington-Bailey |
|
Telephone number of contact: |
+44 (0) 191 511 8500 |
For further information please contact:
|
Shield Therapeutics plc |
|
|
Anders Lundstrom, CEO Santosh Shanbhag, CFO Lucy Huntington-Bailey, Company Secretary |
+44 (0) 191 511 8500 info@shieldtx.com |
|
Nominated Adviser and Joint Broker |
|
|
Peel Hunt LLP |
|
|
James Steel/Christoper Golden |
+44 (0)20 7418 8900 |
|
Joint Broker Cavendish Ltd Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward |
+44 (0)20 7220 0500
|
About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.
ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.